Bora CDMO Bora CDMO

X

Find Brensocatib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

0

US DMFs Filed

US DMFs Filed

0

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

Other Certificates

Other Certificates

0

Other Suppliers

Other Suppliers

0

API REF. PRICE (USD / KG)

0

INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Brensocatib
Also known as: Azd7986, 1802148-05-5, Ins1007, (s)-n-((s)-1-cyano-2-(4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-1,4-oxazepane-2-carboxamide, Brensocatib [usan], Azd 7986
Molecular Formula
C23H24N4O4
Molecular Weight
420.5  g/mol
InChI Key
AEXFXNFMSAAELR-RXVVDRJESA-N
FDA UNII
25CG88L0BB

Brensocatib is an orally bioavailable, small molecule, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), with potential anti-inflammatory activity. Upon oral administration, brensocatib reversibly binds to and inhibits the activity of DPP1, thereby inhibiting the activation of neutrophil serine proteases (NSPs), including neutrophil elastase (NE), during neutrophil maturation. This inhibits the activity of NSPs, and may prevent lung inflammation and injury and improve lung function associated with NSPs-induced respiratory diseases. NSPs, serine proteases released by neutrophils during inflammation, is upregulated in a number of respiratory diseases.
1 2D Structure

Brensocatib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(2S)-N-[(1S)-1-cyano-2-[4-(3-methyl-2-oxo-1,3-benzoxazol-5-yl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide
2.1.2 InChI
InChI=1S/C23H24N4O4/c1-27-19-12-17(7-8-20(19)31-23(27)29)16-5-3-15(4-6-16)11-18(13-24)26-22(28)21-14-25-9-2-10-30-21/h3-8,12,18,21,25H,2,9-11,14H2,1H3,(H,26,28)/t18-,21-/m0/s1
2.1.3 InChI Key
AEXFXNFMSAAELR-RXVVDRJESA-N
2.1.4 Canonical SMILES
CN1C2=C(C=CC(=C2)C3=CC=C(C=C3)CC(C#N)NC(=O)C4CNCCCO4)OC1=O
2.1.5 Isomeric SMILES
CN1C2=C(C=CC(=C2)C3=CC=C(C=C3)C[C@@H](C#N)NC(=O)[C@@H]4CNCCCO4)OC1=O
2.2 Other Identifiers
2.2.1 UNII
25CG88L0BB
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Azd7986

2. Ins-1007

3. Ins1007

4. N-(1-cyano-2-(4-(3-methyl-2-oxo-2,3-dihydrobenzo(d)oxazol-5-yl)phenyl)ethyl)-1,4-oxazepane-2-carboxamide

2.3.2 Depositor-Supplied Synonyms

1. Azd7986

2. 1802148-05-5

3. Ins1007

4. (s)-n-((s)-1-cyano-2-(4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-1,4-oxazepane-2-carboxamide

5. Brensocatib [usan]

6. Azd 7986

7. Azd-7986

8. Ins-1007

9. 25cg88l0bb

10. Chembl3900409

11. (2s)-n-[(1s)-1-cyano-2-[4-(3-methyl-2-oxo-1,3-benzoxazol-5-yl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide

12. (s)-n-((s)-1-cyano-2-(4-(3-methyl-2-oxo-2,3-dihydrobenzo-(d)oxazol-5-yl)phenyl)ethyl)-1,4-oxazepane-2-carboxamide

13. 1,4-oxazepine-2-carboxamide, N-((1s)-1-cyano-2-(4-(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)phenyl)ethyl)hexahydro-, (2s)-

14. Ins 1007

15. Brensocatib [inn]

16. Unii-25cg88l0bb

17. Brensocatib [who-dd]

18. Gtpl9412

19. Schembl16932317

20. Ex-a1866

21. Bdbm50195235

22. Pz1130

23. Who 11097

24. Ac-36222

25. As-84225

26. Bb177302

27. Hy-101056

28. Cs-0020766

29. J3.556.230c

30. A17095

31. D84088

32. A937370

33. (2s)-n-{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide

34. (s)-3-[4-(2-oxo-3-methyl-2,3-dihydrobenzoxazole-5-yl)phenyl]-2-[(hexahydro-1,4-oxazepine-2alpha-yl)carbonylamino]propanenitrile

2.4 Create Date
2016-02-23
3 Chemical and Physical Properties
Molecular Weight 420.5 g/mol
Molecular Formula C23H24N4O4
XLogP32
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count6
Rotatable Bond Count5
Exact Mass420.17975526 g/mol
Monoisotopic Mass420.17975526 g/mol
Topological Polar Surface Area104 Ų
Heavy Atom Count31
Formal Charge0
Complexity699
Isotope Atom Count0
Defined Atom Stereocenter Count2
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Treatment of non-cystic fibrosis bronchiectasis


Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY